Hematologic reactions to carbonic anhydrase inhibitors.
The National Registry of Drug-Induced Ocular Side Effects has received 79 case reports of suspected hematopoietic toxicity caused by carbonic anhydrase inhibitors. Twenty-six of these suspected cases (32%) resulted in death secondary to aplastic anemia, thrombocytopenia, or agranulocytosis. In 54 of these 79, adverse reactions (68%) occurred during the first six months of therapy.
D000086:Acetazolamide / Q000009:adverse effects; D000380:Agranulocytosis / Q000139:chemically induced*; D000741:Anemia, Aplastic / Q000139:chemically induced*; D002257:Carbonic Anhydrase Inhibitors / Q000009:adverse effects*; D004005:Dichlorphenamide / Q000009:adverse effects; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008704:Methazolamide / Q000009:adverse effects; D010198:Pancytopenia / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced*
D002257:Carbonic Anhydrase Inhibitors; D000086:Acetazolamide; D004005:Dichlorphenamide; D008704:Methazolamide